|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
2016
2017
2019
2020
Crealta_Pharmaceuticals
Raptor_Pharmaceutical
|
|
gptkbp:CEO
|
Timothy_P._Walbert
|
|
gptkbp:clinicalTrials
|
ongoing
completed
|
|
gptkbp:community_engagement
|
yes
|
|
gptkbp:employeeCount
|
approximately 500
|
|
gptkbp:focus
|
rare diseases
|
|
gptkbp:founded
|
2008
|
|
gptkbp:founder
|
Timothy_P._Walbert
|
|
gptkbp:headquarters
|
gptkb:Dublin,_Ireland
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Horizon Pharma
|
|
gptkbp:leadership
|
diverse team
|
|
gptkbp:market
|
gptkb:Asia
gptkb:North_America
Europe
|
|
gptkbp:mission
|
improve patients' lives
|
|
gptkbp:partnerships
|
gptkb:Mayo_Clinic
gptkb:Duke_University
gptkb:University_of_Chicago
gptkb:Cleveland_Clinic
|
|
gptkbp:patentType
|
yes
|
|
gptkbp:philanthropy
|
Horizon_Cares
Horizon_Foundation
|
|
gptkbp:products
|
gptkb:Krystexxa
gptkb:Actimmune
Ravicti
Tepezza
|
|
gptkbp:research_focus
|
metabolic disorders
autoimmune diseases
|
|
gptkbp:revenue
|
$1 billion
|
|
gptkbp:sells
|
HZNP
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:sustainability_initiatives
|
yes
|
|
gptkbp:vision
|
be a leader in rare disease treatment.
|